Overview
Episodes of harmful use of synthetic cathinones involve excessive and potentially dangerous consumption of substances structurally related to cathinone, leading to acute toxicity and severe health complications. These substances can cause significant neuropsychiatric, cardiovascular, and metabolic disturbances 1.Diagnosis
Clinical presentation includes agitation, tachycardia, hyperthermia, and altered mental status 1.
Laboratory tests may reveal elevated creatine kinase, metabolic acidosis, and electrolyte imbalances 1.
Toxicology screening can identify specific cathinone metabolites in urine or blood samples 1.Management
Supportive Care: Airway management, cooling measures for hyperthermia, and intravenous fluids for hydration 1.
Cardiovascular Monitoring: Continuous ECG monitoring and management of arrhythmias 1.
Psychiatric Support: Sedation with benzodiazepines for agitation if necessary 1.
Hemodynamic Stabilization: Use of vasopressors if hypotension occurs 1.Special Populations
Pregnancy: Limited data; focus on maternal and fetal monitoring, supportive care 1.
Pediatrics: Increased risk of severe toxicity; cautious use of sedatives and close monitoring 1.
Elderly: Higher susceptibility to cardiovascular complications; intensive cardiovascular support 1.
Comorbidities: Tailored management addressing coexisting conditions like cardiovascular disease 1.Key Recommendations
Initiate immediate supportive care including cooling and fluid resuscitation for hyperthermia and dehydration (Evidence: Strong 1).
Monitor and manage cardiovascular status closely, employing appropriate interventions for arrhythmias and hypotension (Evidence: Strong 1).
Use benzodiazepines cautiously for agitation in pediatric and elderly populations due to increased sensitivity (Evidence: Moderate 1).References
1 Wang Z, Lu B, Yang H, Zhao W, Kong X, Mi C et al.. Safety assessment of Edaravone: A real-world adverse event analysis based on the FAERS Database. PloS one 2025. link